Integrated Whole-Genome Analysis of Hematologic Disorders
4 other identifiers
observational
35
1 country
1
Brief Summary
We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is to analyze all of the genes in the diseased and normal skin sample. By comparing the results of the diseased sample and normal skin cells and the results of the two types of genetic information (DNA and RNA), we should be able to identify genetic changes that are important for the initiation, progression, or treatment response of that particular disorder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2009
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2009
CompletedFirst Submitted
Initial submission to the registry
April 19, 2010
CompletedFirst Posted
Study publicly available on registry
April 21, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 2, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
August 2, 2013
CompletedMay 31, 2018
May 1, 2018
3.9 years
April 19, 2010
May 29, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
to identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression
sample collection at time of routine visit
Interventions
Eligibility Criteria
participants with hematologic disorders
You may qualify if:
- years of age or older
- Patient meets the clinical and/or pathologic criteria for the hematologic disorder being examined.
- Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
You may not qualify if:
- Less than 18 years of age
- Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Stanford University School of Medicine
Stanford, California, 94305, United States
Related Publications (1)
Merker JD, Roskin KM, Ng D, Pan C, Fisk DG, King JJ, Hoh R, Stadler M, Okumoto LM, Abidi P, Hewitt R, Jones CD, Gojenola L, Clark MJ, Zhang B, Cherry AM, George TI, Snyder M, Boyd SD, Zehnder JL, Fire AZ, Gotlib J. Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. Haematologica. 2013 Nov;98(11):1689-96. doi: 10.3324/haematol.2013.092379. Epub 2013 Jul 19.
PMID: 23872309DERIVED
Biospecimen
blood, bone marrow, skin biopsy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
James L Zehnder
Stanford University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Pathology
Study Record Dates
First Submitted
April 19, 2010
First Posted
April 21, 2010
Study Start
September 1, 2009
Primary Completion
August 2, 2013
Study Completion
August 2, 2013
Last Updated
May 31, 2018
Record last verified: 2018-05